Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07613190
NCT07613190Not yet recruitingNot Applicable

Adjunctive Oral Iron Supplementation in Atopic Dermatitis: A Randomized Controlled Trial

Cairo University0 sites124 target enrollmentStarted: May 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
124
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The present randomized controlled trial aims to evaluate the effect of adjunctive oral iron supplementation on disease severity and quality of life in adolescents with mild to moderate atopic dermatitis. In addition, the study will explore whether baseline iron status modifies treatment response and whether changes in iron biomarkers correlate with improvements in clinical severity scores.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
12 Years to 16 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adolescents aged 12 to 16 years.
  • •Diagnosis of atopic dermatitis according to Hanifin and Rajka or UK Working Party criteria.
  • •Mild to moderate disease defined as EASI score 1.1-7.0 for mild and 7.1-21.0 for moderate disease, according to the severity classification of Leshem et al. (2015).
  • •Stable standard-of-care topical therapy for at least two weeks prior to enrolment.
  • •Willingness to maintain baseline topical therapy throughout the study period.
  • •Written informed consent from a parent or legal guardian and assent from the participant will be obtained prior to enrolment.

Exclusion Criteria

  • •Iron-related exclusions
  • •Known iron overload disorders (e.g., hereditary hemochromatosis).
  • •Ferritin above age- and sex-specific upper reference limits for adolescents (based on local laboratory pediatric reference ranges) in the absence of elevated CRP.
  • •Use of oral or intravenous iron supplementation within the previous three months.
  • •Hematologic exclusions
  • •Haemoglobin less than 8 g/dL. Participants excluded on this basis will be referred to the haematology clinic for evaluation and management of severe anaemia, in accordance with the Declaration of Helsinki (Article 37).
  • •Known hemoglobinopathies (e.g., thalassemia major, sickle cell disease).
  • •Active bleeding or known bleeding disorders. Dermatologic exclusions
  • •Presence of other chronic inflammatory skin diseases that may interfere with assessment (e.g., psoriasis, bullous disorders).
  • •Active skin infection requiring systemic antibiotic therapy.
  • •Use of systemic treatments for atopic dermatitis, including:
  • •Systemic corticosteroids
  • •Immunosuppressants
  • •Biologic therapies within the following washout periods: dupilumab ≥12-16 weeks; cyclosporine ≥4 weeks; methotrexate ≥4-6 weeks; systemic corticosteroids ≥2-4 weeks.
  • •Systemic exclusions
  • •Severe chronic illnesses that may affect study participation or safety, including:
  • •Advanced kidney disease
  • •Chronic liver disease
  • •Any other medical condition that, in the investigator's judgment, may interfere with study participation or outcomes.

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Eglal Adel Mostafa Bassiouny

Dr.

Cairo University

Similar Trials

Not yet recruiting
Not Applicable
Understanding the effect of probiotics consumption in improving the Atopic Dermatitis disease
CTRI/2024/06/068558Unique Biotech Ltd.60
Recruiting
Not Applicable
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and AdultsEmollientsAtopic Dermatitis
NCT07358000University Hospital, Caen86
Not yet recruiting
Phase 3
Comparing ARSENICUM ALBUM IN LM POTENCY to INDIVIDUALIZED HOMOEOPATHIC MEDICINE for the treatment of ECZEMA/ATOPIC DERMATITIS
CTRI/2024/11/076955Dr NEETHU V48
Not yet recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic DermatitisAtopic Dermatitis
NCT07479615Shanghai Mabgeek Biotech.Co.Ltd498
Not yet recruiting
Not Applicable
Efficacy of Vitamin D Supplementation In Allergic Rhinitis
CTRI/2025/08/093525Gmers Medical College And Hospital Gotri Vadodara120